Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
2018 ◽
Vol 149
◽
pp. 38
◽
U.A. Matulonis
◽
K.N. Moore
◽
L.P. Martin
◽
I.B. Vergote
◽
C.M. Castro
◽
...